A Dark Vector Cognition product

Philip Morris International 10-Q 2026-09-30

PM · CIK 1413329 · Form 10-Q · Period ended September 30, 2026 · Filed October 23, 2026

Revenue rose 5.5% to $11.4 billion. Operating margin was 42.5%, against 39.3% a year earlier. Net income was $3.31 billion.

7 sections, 413K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Sep 30, 2026Quarter ended Sep 30, 2025Change
Revenue$11.4B$10.8B+5.5%
Operating income$4.87B$4.26B+14.1%
Net income$3.31B$3.48B-4.7%
Diluted EPS$2.12$2.23-4.9%
Cash and equivalents$6.68Bn/an/a
Operating margin*42.5%39.3%+3.2 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 69 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-33708

Philip Morris International Inc.

(Exact name of registrant as specified in its charter)

Virginia13-3435103
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
677 Washington Blvd, Suite 1100StamfordConnecticut06901
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code(203)905-2410

Former name, former address and former fiscal year, if changed since last report

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, no par valuePMNew York Stock Exchange
3.125% Notes due 2027PM27New York Stock Exchange
3.125% Notes due 2028PM28New York Stock Exchange
2.875% Notes due 2029PM29New York Stock Exchange
3.375% Notes due 2029PM29ANew York Stock Exchange
2.750% Notes due 2029PM29DNew York Stock Exchange
3.750% Notes due 2031PM31BNew York Stock Exchange
0.800% Notes due 2031PM31New York Stock Exchange
3.250% Notes due 2032PM32New York Stock Exchange
3.125% Notes due 2033PM33New York Stock Exchange
2.000% Notes due 2036PM36New York Stock Exchange
1.875% Notes due 2037PM37ANew York Stock Exchange
6.375% Notes due 2038PM38New York Stock Exchange
1.450% Notes due 2039PM39New York Stock Exchange
4.375% Notes due 2041PM41New York Stock Exchange
4.500% Notes due 2042PM42New York Stock Exchange
Title of each classTrading Symbol(s)Name of each exchange on which registered
3.875% Notes due 2042PM42ANew York Stock Exchange
4.125% Notes due 2043PM43New York Stock Exchange
4.875% Notes due 2043PM43ANew York Stock Exchange
4.250% Notes due 2044PM44New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer þ Accelerated filer ☐

Non-accelerated filer ☐ Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

At October 16, 2026, there were 1,558,655,629 shares outstanding of the registrant’s common stock, no par value per share.

PHILIP MORRIS INTERNATIONAL INC.

TABLE OF CONTENTS

Page No.
PART I -FINANCIAL INFORMATION
Item 1.Financial Statements (Unaudited)
Condensed Consolidated Statements of Earnings for the
Nine Months Ended September 30, 2026 and 20253
Three Months Ended September 30, 2026 and 20253
Condensed Consolidated Statements of Comprehensive Earnings for the
Nine Months Ended September 30, 2026 and 20254
Three Months Ended September 30, 2026 and 20255
Condensed Consolidated Balance Sheets at
September 30, 2026 and December 31, 20256 – 7
Condensed Consolidated Statements of Cash Flows for the
Nine Months Ended September 30, 2026 and 20258 – 9
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity for the
Nine Months Ended September 30, 2026 and 202510
Three Months Ended September 30, 2026 and 202511
Notes to Condensed Consolidated Financial Statements12 – 42
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations43 – 91
Item 4.Controls and Procedures91
PART II -OTHER INFORMATION
Item 1.Legal Proceedings91
Item 1A.Risk Factors91
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds92
Item 5.Other Information92
Item 6.Exhibits93
Signature94

In this report, “PMI,” “we,” “us” and “our” refer to Philip Morris International Inc. and its subsidiaries.

Trademarks and service marks in this report are the registered property of, or licensed by, the subsidiaries of Philip Morris International Inc. and are italicized.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

Philip Morris International Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings

(in millions of dollars, except per share data)

(Unaudited)

For the Nine Months Ended September 30,
20262025
Net revenues 1 & 2 (Note 13)$32,776$30,286
Cost of sales (Note 1)10,3589,789
Gross profit22,41820,497
Marketing, administration and research costs (Notes 1 & 15)8,8318,474
Impairment of goodwill (Note 5)—41
Corporate expenses and other (Note 1)298463
Operating income13,28911,519
Interest expense, net679748
Pension and other employee benefit costs (Note 4)6337
Earnings before income taxes12,54710,734
Provision for income taxes2,6172,062
Impairment related to the RBH equity investment (Note 13)511—
Equity investments and securities (income)/loss, net (Note 13)330(926)
Net earnings$9,089$9,598
Net earnings attributable to noncontrolling interests521391
Net earnings attributable to PMI$8,568$9,207
Per share data (Note 7):
Basic earnings per share$5.49$5.90
Diluted earnings per share$5.48$5.89

(1) Includes net revenues from related parties of $3,752 million and $3,387 million for the nine months ended September 30, 2026 and 2025, respectively.

(2) Net revenues are shown net of excise tax on products. For the nine months ended September 30, 2026 and 2025, excise tax on products was $42,965 million and $39,495 million, respectively.

See notes to condensed consolidated financial statements.

Philip Morris International Inc. and Subsidiaries

Condensed Consolidated Statements of Earnings

(in millions of dollars, except per share data)

(Unaudited)

For the Three Months Ended September 30,
20262025
Net revenues 1 & 2 (Note 13)$11,438$10,845
Cost of sales (Note 1)3,5843,484
Gross profit7,8547,361
Marketing, administration and research costs (Notes 1 & 15)2,9933,058
Corporate expenses and other (Note 1)(5)40
Operating income4,8664,263
Interest expense, net199230
Pension and other employee benefit costs (Note 4)7314
Earnings before income taxes4,5944,019
Provision for income taxes986751
Equity investments and securities (income)/loss, net (Note 13)86(345)
Net earnings3,5223,613
Net earnings attributable to noncontrolling interests209135
Net earnings attributable to PMI$3,313$3,478
Per share data (Note 7):
Basic earnings per share$2.12$2.23
Diluted earnings per share$2.12$2.23

(1) Includes net revenues from related parties of $1,312 million and $1,307 million for the three months ended September 30, 2026 and 2025, respectively.

(2) Net revenues are shown net of excise tax on products. For the three months ended September 30, 2026 and 2025, excise tax on products was $15,139 million and $14,221 million, respectively.

See notes to condensed consolidated financial statements.

Philip Morris International Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Earnings

(in millions of dollars)

(Unaudited)

For the Nine Months Ended September 30,
20262025
Net earnings$9,089$9,598
Other comprehensive earnings (losses), net of income taxes:
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes of $(129) in 2026 and $410 in 2025249(1,917)
(Gains)/losses transferred to earnings, net of income taxes of $0 in 2026 and $0 in 2025(19)—
Change in net loss and prior service cost:
Net gains (losses) and prior service costs, net of income taxes of $60 in 2026 and $(7) in 2025(75)19
Amortization of net losses, prior service costs and net transition costs, net of income taxes of $(20) in 2026 and $(36) in 2025196133
Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes of $(20) in 2026 and $31 in 2025105(168)
(Gains) losses transferred to earnings, net of income taxes of $26 in 2026 and $13 in 2025(125)(69)
Total other comprehensive earnings (losses)331(2,002)
Total comprehensive earnings9,4207,596
Less comprehensive earnings (losses) attributable to:
Noncontrolling interests427395
Comprehensive earnings attributable to PMI$8,993$7,201

See notes to condensed consolidated financial statements.

Philip Morris International Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Earnings

(in millions of dollars)

(Unaudited)

For the Three Months Ended September 30,
20262025
Net earnings$3,522$3,613
Other comprehensive earnings (losses), net of income taxes:
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes of $10 in 2026 and $(23) in 2025(242)(291)

Showing the first 8K of 168K characters. Open the full section

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Description of Our Company

We are a leading international consumer goods company, actively delivering a smoke-free future. We are evolving our portfolio for the long term to include products outside of the tobacco and nicotine sector. Our current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. Since 2008, we have invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for legal-age adults who would otherwise smoke or use other nicotine-containing consumer products, with the goal of completely ending the sale of cigarettes. This investment includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, we acquired Swedish Match AB ("Swedish Match") – a leader in oral nicotine delivery – creating a global smoke-free combination led by the companies’ IQOS and ZYN brands. As of April 30, 2024, we hold the full rights to commercialize IQOS in the U.S. after reaching an agreement to end our U.S. commercial relationship covering IQOS with Altria Group, Inc. in 2022. Following a robust science-based review, the U.S. Food and Drug Administration (the "FDA") has authorized the marketing of Swedish Match’s General snus and ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables*, General* snus and 20 ZYN nicotine pouch variants also obtained the first-ever Modified Risk Tobacco Product ("MRTP") authorizations from the FDA. We describe the MRTP orders in more detail in the "Business Environment" section of this Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A").

With our smoke-free business now operating at scale across our regions, including growth from our U.S. business, PMI has implemented an evolved organizational model with two primary business units: International and U.S. This change was implemented effective January 1, 2026, and as a result, PMI realigned its reportable segments accordingly. The four geographic segments have been replaced with the following three new reportable segments:

  • International Smoke-Free;

  • International Combustibles; and

  • U.S. (including our wellness business unit, Aspeya).

Our cigarettes are sold in approximately 170 markets, and in many of these markets they hold the number one or number two market share position. We have a wide range of premium, mid-price and low-price brands. Our portfolio is comprised of both international and local brands.

Smoke-Free Business ("SFB”) is the term PMI uses to refer to all of its smoke-free products. SFB also includes wellness products, as well as consumer accessories.

Smoke-free products (also referred to herein as "SFPs") is the term PMI uses to refer to all of its products that provide nicotine without combusting tobacco, such as heat-not-burn, e-vapor, and oral smokeless, and that therefore generate far lower levels of harmful chemicals. As such, these products have the potential to present less risk of harm versus continued smoking.

IQOS, ZYN and VEEV are the leading brands in our SFPs portfolio. As of September 30, 2026, our smoke-free products were available for sale in 110 markets.

With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas. The business strategy of our wellness unit, Aspeya, currently focuses on developing and commercializing primarily oral consumer wellness offerings. This includes medical and non-recreational cannabinoid products (including CBD), in line with applicable regulatory requirements, though any revenue related to cannabinoids is expected to be negligible in the near to medium term.

We use the term net revenues to refer to our operating revenues from the sale of our products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. Our net revenues and operating income are affected by various factors, including the volume and mix of products we sell, the price of our products and changes in currency exchange rates. Mix is a term used to refer to the proportionate value of premium-price brands to mid-price or low-price brands in any given market (product mix). "Mix" can also refer to the proportion of shipment volume in more profitable

markets versus shipment volume in less profitable markets (geographic mix). "Other” also includes the currency-neutral net revenue variance attributable to the restructuring of distribution terms in certain markets.

Our cost of sales consists primarily of: tobacco leaf, non-tobacco raw materials, labor and manufacturing costs; shipping and handling costs; and the cost of devices produced by third-party electronics manufacturing service providers. Estimated costs associated with device warranty programs are generally provided for in cost of sales in the period the related revenues are recognized.

Our marketing, administration and research costs include the costs of marketing and selling our products, other costs generally not related to the manufacture of our products (excluding corporate expenses and other), and costs incurred to develop new products. The most significant components of our marketing, administration and research costs are marketing and sales expenses and general and administrative expenses.

Corporate expenses and other include certain other expenses related to foreign currency gains/losses and compensation expense related to restricted share units and performance share units awards, which were reclassified from cost of sales and marketing, administration and research costs.

Executive Summary

The following executive summary provides the business update and significant highlights from the "Discussion and Analysis" that follows.

Consolidated Operating Results for the Nine Months Ended September 30, 2026

  • Net Revenues** - Net revenues of $32.8 billion for the nine months ended September 30, 2026, increased by $2.5 billion, or 8.2%, from the comparable 2025 amount. The change in our net revenues from the comparable 2025 amount was driven by the following (variances not to scale with year-to-date results):

293

For the nine months ended September 30, 2026, net revenues increased by 8.2%. Net revenues, excluding currency and acquisitions/divestitures, increased by 5.9%, mainly reflecting: a favorable pricing variance mainly driven by international combustibles, and higher international smoke-free volumes; partly offset by unfavorable volume/mix, mainly driven by lower international combustibles and U.S. volumes in the first quarter.

Net revenues by product category for the nine months ended September 30, 2026 and 2025 are shown below:

727 730

Note: Sum of product categories might not foot to total PMI due to rounding

  • Diluted Earnings Per Share** - The changes in our reported diluted earnings per share (“diluted EPS”) for the nine months ended September 30, 2026, from the comparable 2025 amounts, were as follows:
Diluted EPS% Change
For the nine months ended September 30, 2025$5.8

Showing the first 8K of 228K characters. Open the full section

Item 4. Controls and Procedures.

PMI carried out an evaluation, with the participation of PMI’s management, including PMI’s Group CEO PMI and Group Chief Financial Officer, of the effectiveness of PMI’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation, PMI’s Group CEO PMI and Group Chief Financial Officer concluded that PMI’s disclosure controls and procedures are effective. There have been no changes in PMI’s internal control over financial reporting during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, PMI’s internal control over financial reporting.

Part II - OTHER INFORMATION

Item 1.Legal Proceedings.

See Note 9. Contingencies of the Notes to the Condensed Consolidated Financial Statements included in Part I – Item 1 of this Form 10-Q for a discussion of legal proceedings pending against Philip Morris International Inc. and its subsidiaries.

Item 1A. Risk Factors.

Information regarding Risk Factors appears in “Management's Discussion and Analysis of Financial Condition and Results of Operations – Cautionary Factors That May Affect Future Results,” in Part I – Item 2 of this Form 10-Q and in Part I – Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2025.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Our share repurchase activity for each of the three months in the quarter ended September 30, 2026, was as follows:

PeriodTotal Number of Shares RepurchasedAverage Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs
July 1, 2026 – July 31, 2026—$——$—
August 1, 2026 – August 31, 2026—$——$—
September 1, 2026 – September 30, 2026—$——$—
Pursuant to Publicly Announced Plans or Programs—$—
July 1, 2026 – July 31, 2026 (1)3,929$179.47
August 1, 2026 – August 31, 2026 (1)2,699$179.69
September 1, 2026 – September 30, 2026 (1)3,676$188.62
For the Quarter Ended September 30, 202610,304$182.79

(1)Shares repurchased primarily represent shares tendered to us by employees who vested in restricted and performance share unit awards and used shares to pay all, or a portion of, the related taxes.

Item 5. Other Information.

During the three months ended September 30, 2026, no director or officer of PMI adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as such terms are defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits.

10.1Separation Agreement and Release with Emmanuel Babeau, dated July 6, 2026 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed July 9, 2026).
31.1Certification of the Registrant's Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification of the Registrant's Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1Certification of the Registrant's Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2Certification of the Registrant's Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema.
101.CALXBRL Taxonomy Extension Calculation Linkbase.
101.DEFXBRL Taxonomy Extension Definition Linkbase.
101.LABXBRL Taxonomy Extension Label Linkbase.
101.PREXBRL Taxonomy Extension Presentation Linkbase.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PHILIP MORRIS INTERNATIONAL INC.
/s/ MASSIMO ANDOLINA
Massimo Andolina
Group Chief Financial Officer
October 23, 2026